Nasal Sprays Containing Mometasone Furoate Can Be Used Prophylactically in COVID-19 Infection and Related Smell Disorders

Year 2023, Volume: 13 Issue: 3, 537 - 540, 11.09.2023

Murat Enöz , Mücahit Özdemir , Bahattin Yalcin

https://doi.org/10.33808/clinexphealthsci.1094759

Abstract

Objective: We aimed to emphasize the possible beneficial effects of intranasal sprays containing mometasone furoate, especially for preventive treatment or supportive treatment in patients with olfactory disorders due to damage to the olfactory area, or for regular use in healthcare workers with a high risk of close contact.
Methods: Preventive and therapeutic scientific studies are continuing around the world for viral spread and viral damage associated with the Coronavirus disease 2019 (COVID-19) pandemic. We investigated the attachment of the COVID-19 virus in the nose and entry into the body with the crystal structure of the spike and Angiotensin-Converting Enzyme 2 (ACE-2) proteins, a molecular docking study. This scientific study is the first in-silico study to investigate the possible antiviral effects of Mometasone furoate molecules on spike protein and to show the antiviral effect of mometasone furoate on COVID-19.
Results: We think that nasal sprays containing mometasone furoate can be used prophylactically in patients with COVID-19 infection due to its antiviral effect, and it may be beneficial to use sprays containing mometasone furoate before the symptoms of upper respiratory tract infection begin in patients.
Conclusions: The role of these molecules in the treatment of acute smell disorders associated with COVID-19 infection and their antiviral effects on coronavirus should be investigated by conducting extensive scientific studies on the subject.

Keywords

Anosmia, Coronavirus, Mometasone furoate, Prevention, Olfactory disorders

References

• Zitt M, Kosoglou T, Hubbell J. Mometasone Furoate Nasal Spray. Drug-Safety 2007;30:317–326.
• Onrust Susan V, Lamb Harriet M. Mometasone Furoate. Drugs 1998;56:725–745.
• Baldwin Claudine M, Scott Lesley J. Mometasone Furoate. Drugs 2008;68: 1723–1739.
• Robert Davies J, Harold Nelson S. Once-daily mometasone furoate nasal spray: Efficacy and safety of a new intranasal Glucocorticoid for Allergic Rhinitis Clin Ther 1997;19(1):27-38.
• Kasiri H, Rouhani N, Salehifar E, Ghazaeian M, Fallah S. Mometasone furoate nasal spray in the treatment of patients with COVID-19 olfactory dysfunction: A randomized, double blind clinical trial. Int. Immunopharmacol 2021;98:107871.
• Abdelalim Ahmed A, Mohamady Abdelaal A, Elsayed Rasha A, Elawady Mona A, Ghallab Abdelhakim F. Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: A randomized controlled trial. Am J Otolaryngol 2021;42(2):102884.
• Trott O, Olson Arthur J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem 2010;31(2):455-461.
• Eberhardt J, Santos-Martins D, Tillack Andreas F, Forli, S. AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings. J Chem Inf Model 2021;61:3891-3898.
• Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, Wang X. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020;581(7807):215-220.
• Xiaoming Sean C, Matthew C, Curtis H, Prudence B. Solid state characterization of mometasone furoate anhydrous and monohydrate forms. J Pharm Sci 2005;94(11):2496-2509.
• BIOVA Dassault Systèmes, Discovery Studio Visualizer 2021, San Diego, CA, USA, 2017.
• Pettersen Eric F, Goddard Thomas D, Huang Conrad C, Couch Gregory S, Greenblatt Daniel M, Meng Elaine C, Ferrin Thomas E. UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem 2004;25(13):1605-12.
• Matsuyama S, Kawase M, Nao N, Shirato N, Ujike M, Kamitani W, Shimojima M, Fukushi S. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. J Virol 2020;95(1):e01648-20.
• Webster Katie E, O'Byrne L, MacKeith S, Philpott C, Hopkins C, Burton Martin J. Interventions for the prevention of persistent post-COVID-19 olfactory dysfunction. Cochrane Database Syst Rev 2021;22;7(7):CD013877.
• Carrillo-Larco Rodrigo M, Altez-Fernandez C. Anosmia and dysgeusia in COVID-19: A systematic review. Wellcome Open Res 2020;13(5):94.
• Pang Khang W, Chee J, Subramaniam S, Ng Chew L. Frequency and Clinical Utility of Olfactory Dysfunction in COVID-19: a Systematic Review and Meta-analysis. Curr Allergy Asthma Rep 2020;20(12):76.
• Rashid Rasheed A, Zgair A, Al-Ani Raid M. Effect of nasal corticosteroid in the treatment of anosmia due to COVID-19: A randomised double-blind placebo-controlled study. Am J Otolaryngol 2021;42(5):103033.
• Singh Chandra V, Jain S, Parveen S. The outcome of fluticasone nasal spray on anosmia and triamcinolone oral paste in dysgeusia in COVID-19 patients. Am J Otolaryngol 2021;42(3):102892.
• Meng X, Deng Y, Dai Z, Meng Z. COVID-19 and anosmia: A review based on up-to-date knowledge. Am J Otolaryngol 2020;41(5):102581.
• Bilinska K, Jakubowska P, Von Bartheld Cristopher S, Butowt R. Expression of the SARS-CoV-2 Entry Proteins, ACE2 and TMPRSS2, in Cells of the Olfactory Epithelium: Identification of Cell Types and Trends with Age. ACS Chem Neurosci 2020;11(11):1555-1562.
• Eliezer M, Hautefort C, Hamel Anne L, Verillaud B, Herman P, Houdart E, Eloit C. Sudden and Complete Olfactory Loss of Function as a Possible Symptom of COVID-19. JAMA Otolaryngol Head Neck Surg 2020;146(7):674-675.
• Yao L, Yi X, Pinto Jayant M, Yuan X, Guo Y, Liu Y, Wei Y. Olfactory cortex and Olfactory bulb volume alterations in patients with post-infectious Olfactory loss. Brain Imaging Behav 2018;12(5):1355-1362.
• Miyazawa D, Kaneko G. Clinical trials of inhaled beclomethasone and mometasone for COVID-19 should be conducted. J Med Virol 2021;93(2):637-638.
• Maes T, Bracke K, Brusselle Guy G. COVID-19, Asthma, and Inhaled Corticosteroids: Another Beneficial Effect of Inhaled Corticosteroids? Am J Respir Crit Care Med 2020;202(1):8-10.